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Background. The degree of proteinuria in patients with diabetes
correlates strongly with both an increase in progression of ne-
phropathy as well as cardiovascular events. Moreover, post hoc
analyses of recent clinical trials support the concept that reduc-
tions of blood pressure and proteinuria correlate with a slowed
progression of nephropathy. Both angiotensin converting enzyme
(ACE) inhibitors and the nondihydropyridine calcium antago-
nists, (non-DHPCAs) reduce both arterial pressure and protein-
uria in those with diabetic nephropathy.
Methods. The present randomized, open label, parallel group
designed study tests the hypothesis that, at similar levels of blood
pressure, the combination of an ACE inhibitor, trandolapril (T)
with the non-DHPCA, verapamil (V) produces a greater reduc-
tion in proteinuria over either agent alone at one year. Thirty-
seven participants, mean age 59.6 6 5.8 years, with nephropathy
(baseline creatinine 1.4 6 0.3 mg/dl and proteinuria of 1342 6 284
mg/dl) secondary to type 2 diabetes completed the study. Doses of
drug were titrated in each group over eight weeks to achieve a
goal blood pressure of , 140/90 mm Hg. All participants were
counseled to ingest a sodium diet of , 120 mEq/day.
Results. Proteinuria reduction from baseline was significantly
greater in the T1V group compared to either T alone (233 6
8%, T vs. 262 6 10%, T1V; P , 0.001) or V alone (227 6 8%,
V vs. 262 6 10%, T1V; P , 0.001). No significant differences in
either glomerular filtration rate, arterial pressure, fasting blood
glucose or urinary sodium excretion were noted at one year. The
mean daily dose of the individual components of T1V (2.9 6 0.8
mg, T/219 6 21.1 mg V) was significantly lower than the dose of
either T alone 5.5 6 1.1 mg/day (P , 0.01) or V alone 314.8 6
46.3 mg, given in two divided doses (P , 0.01).
Conclusion. These data support the concept that the combina-
tion of an ACE inhibitor with a non-DHPCA reduce proteinuria
to a greater extent than either agent alone. This added antipro-
teinuric effect occurs at lower doses of each drug and is indepen-
dent of further reductions in arterial pressure. These findings
could have ramifications for slowing renal disease progression in
patients with nephropathy from type 2 diabetes.
In clinical studies of patients with diabetes, increasing
levels of proteinuria strongly correlate with progression of
nephropathy [1–5]. Conversely, a blunted rise or reduction
in proteinuria is associated with a slowed progression of
diabetic nephropathy [1–11]. These effects on proteinuria
have been found to be, in part, independent of blood
pressure reduction itself in the presence of angiotensin
converting enzyme (ACE) inhibitors [9–11].
Animal studies, some using 24-hour blood pressure
monitoring, clearly indicate that at similar levels of blood
pressure both ACE inhibitors and nondihydropyridine cal-
cium antagonists (nonDHPCAs) significantly decrease pro-
teinuria [12, 13]. Moreover, animal studies that combined a
nonDHPCA with an ACE inhibitor demonstrated further
attenuation in the rise of proteinuria as well as prevention
of mesangial matrix expansion and glomerulosclerosis
when compared to either agent alone [12–14]. This is not
true, however, for the combined use of ACE inhibitors with
dihydropyridine calcium antagonists [15]. Similar results
have also been reported with an ACE inhibitor/dihydropyr-
idine calcium antagonist combination in a short-term clin-
ical study [16].
Based on these observations one could, therefore, pos-
tulate that in a high-risk group, such as those with diabetic
nephropathy, renal insufficiency and hypertension, the
combination of an ACE inhibitor with a non-DHPCA
would produce a greater antiproteinuric effect as compared
to either agent alone. Moreover, these effects may be
independent of further arterial pressure reduction over the
individual components of the combination. Thus, the cur-
rent study was designed to examine the hypothesis that, at
similar levels of blood pressure reduction, the combination
of an ACE inhibitor, trandolapril (T), with a non-DHPCA,
verapamil SR (V), produces greater reductions in protein-
uria when compared to either agent alone.
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METHODS
Forty-four participants with evidence of nephropathy
from type 2 diabetes were recruited from four different
clinical centers. Thirty-seven of the 44 (84%) participants
completed the one year trial. The data from these partici-
pants form the basis of this report.
All study participants gave written informed consent to
participate in the trial prior to enrollment. Informed con-
sent was reviewed and approved by each institution that
participated in the trial.
Study design
The study was an open label, randomized, parallel group
design that included a placebo run-in period (Fig. 1). It was
conducted at four different centers throughout the United
States. The trial extended over a one-year period following
randomization. None of the groups were stratified by any
measured parameter prior to randomization.
The primary endpoint of the study was a 25% greater
reduction in urinary protein excretion in the combination
group of over the groups randomized to either agent alone.
Reduction in proteinuria was predicted to occur at levels of
blood pressure that were comparable among the three
groups. Secondary endpoints included changes from base-
line glomerular filtration rate (GFR), urinary albumin
excretion and effects on tubular proteinuria as assessed by
excretion of b2-microglobulin.
Following withdrawal of all antihypertensive medica-
tions, each participant was randomized to one of three
groups of antihypertensive therapy. Each was given a
placebo for two weeks until supine diastolic blood pres-
sure was . 95 mm Hg on a single visit. All blood
pressures were measured in duplicate, five minutes apart,
and the mean value of each used for analysis. Sitting
blood pressures were also measured but not used for
primary analysis. At the end of the two-week, placebo
run-in period, each participant had his or her GFR
measured by 99Tc-DTPA. All measurements of blood
pressure and GFR were performed between 8 a.m. and
10 a.m.. Additionally, two consecutive 24-hour urine
determinations for total protein, albumin, creatinine,
b2-microglobulin and sodium were obtained. The meth-
odology for these assessments is published elsewhere
[17, 18].
The starting dose of the T-group was 2 mg/day, the V
group, 180 mg/day, and the combination group, T1V, 2/180
mg/day. Doses were titrated to achieve a supine diastolic
blood pressure of , 90 mm Hg. The maximum titratable
dose of T was 8 mg/day, V, 180 mg twice daily or T1V,
4/240 mg/day. If additional blood pressure reduction was
needed furosemide 40 mg/day was added. Thirty-five of 37
(91%) participants received furosemide for blood pressure
control during the study. The remaining details of the
protocol may be found in Figure 1.
Study participants
Four different clinical centers were involved with partic-
ipant recruitment. The inclusion and exclusion criteria of
participants into this trial are found in Table 1. The study
population was restricted to participants with nephropathy
associated with type 2 diabetes. History, laboratory and
ophthalmologic examinations largely determined the diag-
nosis of nephropathy.
Statistical analysis
All data are expressed as mean 6 SD from the mean.
Comparisons between groups were assessed by an analysis
of variance. Additionally, an analysis of covariance was
performed to evaluate whether changes in proteinuria were
due to effects of body wt or fasting blood glucose. A
Fig. 1. Protocol of blood pressure measured monthly. *GFR and 24-hour urinary excretion of protein, albumin, creatinine, b2-microglobulin and
sodium were measured every three months. Abbreviations are: T, trandolapril, V, verapamil SR; T/V, trandolapril 1 verapamil SR.
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Student’s t-test was used to compare the change from
baseline proteinuria, mean arterial pressure and b2-micro-
globlin in each group. Given the small sample size we used
a Bonferonni correction in our analyses to reduce the
probability of committing a Type I error. Differences were
regarded as significant when P , 0.05.
The study was designed with 80% power to detect a 25%
further reduction in proteinuria in the T1V group as
compared to either the T or V groups alone. We assumed
a 30% proteinuria reduction in the T-group and a 25%
proteinuria reduction from baseline in the V group. Given
the size of the study, all values of proteinuria and albumin-
uria were log transformed. Thirty-four percent of partici-
pants in the T-group, 27% in the V group and 62% in the
T1V group demonstrated reduced levels of proteinuria
with therapy. Therefore, the power to detect a 25% differ-
ence in reduction between the T1V group versus the
individual agents was adequate.
RESULTS
General
Thirty-seven of the 44 recruited subjects, 84%, com-
pleted the one-year trial. The reasons for discontinuance of
the study by these seven subjects are noted in Table 2. An
analysis of the baseline data of dropouts versus those who
completed the study did not reveal any significant differ-
ences (data not shown). The mean age of the study
participants was 59.6 6 5.9 years. The average duration of
diabetes was 10.6 6 7.2 years and 13.7 6 5.8 years for
hypertension. The baseline characteristics for each group of
study participants that completed the trial are summarized
in Table 3.
Systemic and renal effects
The systemic and renal hemodynamic effects of the
study participants are summarized in Table 4. No differ-
ences in baseline fasting blood glucose values were
present between any of the groups (191 6 36 mg/dl, T vs.
184 6 44 mg/dl, V, vs. 201 6 44 mg/dl, T1V). Likewise,
while sodium intake was reduced from baseline in each
group, there were no differences between groups (Table
4). Lastly, neither baseline value of body wt (P 5 0.49),
fasting glucose (P 5 0.31) or GFR (P 5 0.35) predicted
the changes in proteinuria.
The average mean arterial pressure for each group was
not significantly different at baseline. However, at three
time points, one month, five months and six months there
was a 3 to 4 mm Hg lower mean arterial pressure in the
combination group versus either the T or V group alone
(Fig. 2). This difference in mean pressure was primarily
related to differences in systolic blood pressure between
the groups. These differences in systolic pressure alone,
however, were not statistically significant (P 5 0.062).
Moreover, no other differences in systolic or diastolic
pressure were noted throughout the study (data not
shown). Additionally, there were no significant within or
between group differences in pulse rate either at baseline
or when measured throughout the study (data not shown).
The relationship between the mean percent reduction in
proteinuria and mean arterial pressure at one year is shown
in Figure 3 for each group. Note that the relatively greater
reduction in proteinuria in the T1V group was not due to
a greater reduction in mean arterial pressure when com-
pared to the other groups. The trends in proteinuria for
each group over the one year trial are shown in Figure 4.
Likewise, albuminuria was reduced in all groups. There
were proportionally similar reductions in albuminuria com-
pared to proteinuria in all groups (Table 4).
b2-microglobulin excretion, a marker of proximal tubular
Table 1. Inclusion/exclusion criteria
Inclusion criteria
r 5 year history of Type 2 diabetes mellitus documented by medical
history
r 5 year history of Stage I hypertension
r Urinary protein excretion of .300 mg/day
Exclusion criteria
Presence of
r Secondary forms of hypertension
r Serum creatinine .2.0 mg/dl or creatinine clearance ,55 ml/min.
r Cerebrovascular accident, convulsive disorder, or hypertensive
encephalopathy within the previous year.
r Congestive heart failure (for example, ejection fraction ,40%)
r Severe bradycardia, clinically significant cardiac dysrhythmia.
r History of myocardial infarction within the previous three months.
r Known hypersensitivity, serious adverse reaction or intolerance to
calcium antagonists and/or ACE inhibitors.
r Clinically significant hepatic dysfunction as determined by liver
function tests.
r Clinically significant hematological abnormalities.
r Any medical or surgical condition that might interfere with drug
absorption, metabolism or excretion.
r Amyloidosis as determined by subcutaneous fat pad biopsy.
r Participation in another study during the 30 days prior to study
entry and during the study.
r Required use of: ACE inhibitors, anti-arrhythmic drugs, digitalis
glycosides, MAO inhibitors, and psychotropic drugs such as major
tranquilizers, antidepressants, central nervous system stimulants
and depressants.
r Any medication containing phenylpropanolamine or
pseudoephedrine.
r Acute or chronic administration of non-steroidal anti-inflammatory
drugs.
r Potassium sparing agents.
Table 2. Reasons for discontinuation
Reasons for
stopping the study Verapamil Trandolapril
Trandolapril 1
Verapamil







Parentheses indicate percent of people in that group.
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dysfunction was similar at baseline among the groups
(Table 4). It was significantly reduced, however, in the
presence of both the ACE inhibitor as well as the combi-
nation of T1V (Table 4). Verapamil alone did not effect its
excretion (Table 4).
The mean daily dose of T alone was 5.5 6 1.1 mg versus
2.9 6 0.8 mg/day in the T1V group (P , 0.03). Likewise,
a higher dose of V was ingested, 157.4 6 39.3 mg given
twice daily (314.8 6 46.3 mg/day), in the V alone group
versus 219 6 21.1 mg/day in the T1V group (P , 0.05).
Thus, a lower dose of both T and V was required to achieve
similar levels of blood pressure reduction, yet with greater
reduction in proteinuria when compared to the individual
agents.
DISCUSSION
This study is the first to demonstrate that the combina-
tion of a non-DHPCA with an ACE inhibitor produces and
Fig. 2. Mean arterial pressure in each group
over the one year duration of the study.
Abbreviations are: T, trandolapril; V, verapamil
SR; T/V, trandolapril 1 verapamil SR. Symbols
are: (M) V; (L) T; () T1V. *P , 0.05
compared to either V alone or T alone.








Male/female 7/4 9/3 9/5
Age years 61 6 5 58 6 6 60 6 6
Ethnicity %
C/AA/O 4(36);5(46);2(18) 7(58);4(33);1(8) 7(50);5(36);2(14)
Diabetes Hx. years 12 6 6 9 6 7 11 6 6
Hypertension Hx. years 14 6 7 12 6 6 15 6 7
Body weight kg 87 6 5 90 6 6 91 6 6
Abbreviations are: C, Caucasian; AA, African American; O, other; Hx., what?.
Table 4. Baseline and one year systemic and renal hemodynamic profiles of participants with NIDDM nephropathy
Verapamil (N 5 11) Trandolapril (N 5 12) Verapamil1Trandolapril (N 5 14)
Baseline One year Baseline One year Baseline One year
Arterial pressure
Systolic mm Hg 176 6 12 138 6 11a 172 6 11 139 6 10a 169 6 13 137 6 12a
Diastolic mm Hg 107 6 5 88 6 6a 102 6 6 87 6 7a 106 6 6 86 6 5a
Renal
GFR (ml/min/1.73 m2) 69 6 18 67 6 17 72 6 19 71 6 15 74 6 18 75 6 19
UproteinV (mg/day) 1349 6 386 985 6 279 1274 6 326 840 6 246
a 1403 6 397 592 6 201ab
UalbuminV (mg/day) 604 6 187 421 6 152
a 616 6 202 399 6 176a 672 6 198 234 6 102ab
UsodiumV (mmol/day) 197 6 38 131 6 34 175 6 31 128 6 24 202 6 29 135 6 21
b2-microglobulin mg/mg Cr. 1.5 6 0.5 1.3 6 0.4 0.9 6 0.4 0.3 6 0.1
a 1.3 6 0.4 0.6 6 0.2a
GFR 5 glomerular filtration rate
a P , 0.05 compared to baseline values
b P , 0.05 compared to one year values of individual agents
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sustains relatively greater reductions in proteinuria com-
pared to higher doses of either agent alone. Moreover, the
reduction in proteinuria could not be differentiated by the
degree of blood pressure reduction, glucose control, b2-
microglobulin excretion or sodium intake among the dif-
ferent groups. Lastly, this study also confirms previous
reports that nonDHPCAs, in contrast to dihydropyridine
calcium antagonists, either do not affect or reduce tubular
proteinuria [19, 20].
Based on the results of recent clinical trials in both
diabetic and non-diabetic subjects the results of this
small study may have far reaching implications. Data
from clinical trials in subjects with non-diabetic renal
disease clearly indicate that reductions in proteinuria
correlate with preservation of renal function [4, 5, 21]. It
further appears that subjects with nondiabetic renal
disease who have proteinuria of greater than one gram
per day garner the greatest benefit when proteinuria is
reduced [4, 5]. Moreover, one trial of nondiabetic pa-
tients with proteinuria demonstrated that the greater the
degree of proteinuria reduction the greater the slowing
of renal disease progression [5].
The results of trials in diabetic nephropathy, however,
generate even more impressive results with lesser degrees
of proteinuria. In a recent seven-year study of normoten-
sive subjects with type 2 diabetes and microalbuminuria, a
blunted rise in microalbuminuria correlated with greater
preservation of renal function in comparison to placebo [6].
Moreover, data from other large-scale trials in type 1
diabetes demonstrate similar results [7].
It should be noted, however, that as in patients with
nondiabetic renal disease, those with diabetic nephropathy
have two factors that confound the interpretation of clinical
trial results. First, is the possibility of disparate degrees of
blood pressure control achieved between the groups. Sec-
ondly, those with the greatest amounts proteinuria, gener-
ally . 1 gram per day, garner a relatively greater benefit
from blood pressure control over the same period of time
compared to those with lesser degrees of proteinuria. This
is due to the fact that they have a greater degree of renal
dysfunction and hence, more likely to progress. Thus, to
demonstrate that reductions in levels of proteinuria of , 1
gram per day correlate with preservation of renal function,
the follow-up time must be markedly lengthened. This is
evident by the results of recent studies in such patients [6].
Thus, in diabetes preservation of renal function may be
seen at lower levels of proteinuria than those observed in
nondiabetic renal disease. Our study was not designed to
assess preservation of renal function, but given the rela-
tively small variance in proteinuria, compared to patients
with nondiabetic renal disease, we were able to demon-
strate an effect on proteinuria reduction over a one year
period. This may not have been seen in a similar number of
nondiabetic patients due to generally much higher variance
in proteinuria levels [5].
One possible explanation for the additive effects of T1V
on proteinuria, independent of blood pressure reduction,
may relate to their effects on glomerular size selectivity. It
is known that both ACE inhibitors and non-DHPCAs
reduce proteinuria through reductions in glomerular size
selectivity [22, 23]. While we did not directly measure
changes in membrane permeability, we did evaluate factors
known to affect protein excretion including blood pressure
and sodium excretion. It is known that high sodium intake
reduces the antiproteinuric effects of both ACE inhibitors
and non-DHPCAs [24, 25]. An analysis of covariance did
not reveal any effect of blood pressure or sodium intake on
the degree of proteinuria change. Moreover, antiprotein-
uric effects have been demonstrated in the range of sodium
intake observed in our study [2–3]. Therefore, the degree of
dietary salt restriction would not have explained the addi-
tive effect on albuminuria reduction in the combination
treatment group.
Another factor that may explain the additive effect of
this drug combination on proteinuria reduction is the small
difference at distinct time points in mean arterial pressure
reduction between groups. Previous studies have noted that
a four to six mm Hg difference in mean arterial pressure
between groups contributes substantially to reduction in
proteinuria in those with diabetic nephropathy [7, 8, 10]. In
our study the greatest difference in mean blood pressure, at
any given time point, between the T1V group and the
others was 4 mm Hg. This was noted at three different time
points throughout the study. Therefore, while this differ-
ence in blood pressure may have contributed to the reduc-
tion of proteinuria, it cannot totally explain the additive
effect over the entire study period.
Fig. 3. The percent reduction from baseline in both proteinuria (f) and
mean arterial pressure ( ) at one year. Abbreviation T/V is trandolapril
1 verapamil SR. #P , 0.05 difference between albuminuria reduction and
MAP in a given group. *P , 0.05 different from other groups of
albuminuria reduction.
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Based on the available data both blood pressure eleva-
tions and proteinuria are well known predictors of cardio-
vascular events and renal failure in diabetic patients [1].
Our observations support the concept that a combination
of an ACE inhibitor with a non-DHPCA will not only
reduce blood pressure but will also produce additive reduc-
tions in proteinuria in patients with type 2 diabetes. This
antiproteinuric effect coupled with arterial pressure reduc-
tion to , 130/85 mm Hg may translate into slower progres-
sion of renal disease [26].
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